Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
European Stocks Rise as U.S. Inflation Data Eases Fed Rate Hike Fears 
UK Economy Posts Surprise June Growth as World Cup and Hot Weather Lift Activity 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Asian Currencies Edge Higher as Soft US Inflation Weighs on Dollar 
France Inflation Rises 2.4% in July as Consumer Prices Increase 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Oil Prices Rise as Hormuz Tensions Threaten Global Supply 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Add as a preferred source on Google
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
